Bristol-Myers Squibb stock holds near consensus target as Opdivo patent suit and EPS guidance shape outlook

Published on 09/15/2026 at 21:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bristol-Myers Squibb stock closed at USD 64.08 on September 14, 2026 on the NYSE, about 3.5 percent below the USD 66.33 analyst consensus target. Current guidance for fiscal 2026 non-GAAP EPS stands in a range of USD 6.75 to USD 7.00, with consensus at USD 6.95.

Pharmazeutisches Forschungslabor mit NYC-Skyline, Wissenschaftler bei der Arbeit — Bristol-Myers Squibb US1078421011 zeigt Wissenschaftler in modernem New Yorker Onkologie-Labor mit Stadtpanorama, Illustration mit AI erstellt.

Bristol-Myers Squibb stock (ISIN US1078421011) most recently closed at USD 64.08 on the New York Stock Exchange on September 14, 2026, leaving the shares trading about USD 2.25, or roughly 3.5 percent, below the prevailing analyst consensus price target of USD 66.33 per MarketBeat data.MarketBeat on September 15, 2026 reports that Bristol-Myers Squibb currently carries a consensus rating of Moderate Buy and that the average price target stands at USD 66.33, with FY 2026 EPS guidance in a non-GAAP range of USD 6.75 to USD 7.00 and a consensus estimate of USD 6.95 per share.

Patent suit over Opdivo biosimilar adds a legal overhang

As Reuters reported on September 15, 2026, Bristol-Myers Squibb and its partner Ono Pharmaceutical have sued Amgen in Delaware federal court in an effort to block a proposed biosimilar version of Opdivo, the company’s blockbuster cancer immunotherapy drug.

The complaint, which Bloomberg Law notes was initially filed under seal on September 8, 2026, alleges that Amgen’s candidate, known as ABP 206, infringes seven patents related to Opdivo, underscoring the strategic importance of defending key oncology franchises as patent expiry and competitive pressure loom.

For investors, the suit introduces a legal counter-factor alongside the fundamental story: while protecting Opdivo’s revenue base can support Bristol-Myers Squibb’s long-term cash flows, litigation outcomes and potential settlement terms remain uncertain and could influence the valuation assigned to the company’s immuno-oncology portfolio.

Guidance and EPS expectations underpin valuation

According to MarketBeat on September 15, 2026, Zacks Research recently boosted its estimate for Bristol-Myers Squibb’s EPS in a coming quarter by USD 0.01 per share to USD 1.55, while the consensus forecast for the company’s current full-year earnings stands at USD 6.95 per share.

The same MarketBeat overview indicates that Bristol-Myers Squibb has set its fiscal 2026 non-GAAP EPS guidance at 6.750 to 7.000 dollars, so the consensus projection of USD 6.95 sits almost exactly in the middle of that range and reflects analysts’ expectation that the company can deliver on its earnings framework despite competitive and patent-related headwinds.MarketBeat highlights that the Moderate Buy consensus rating is anchored in this guidance and the associated earnings trajectory.

For valuation, the interplay between guidance and price targets is important: with the stock at USD 64.08 on September 14, 2026 and the average analyst target at USD 66.33, the implied upside of about 3.5 percent suggests that the market already prices in much of the anticipated earnings growth, leaving less room for disappointment in light of ongoing patent expiry risks for products such as Eliquis highlighted by Pandaremit on September 15, 2026.

Analyst targets and one-year performance in focus

Beyond the average consensus, individual analyst views vary: according to Futunn on September 15, 2026, RBC Capital maintains Bristol-Myers Squibb with a Hold rating and a target price of USD 64, essentially in line with the September 14, 2026 closing price of USD 64.08.

This RBC target compares with the broader consensus level of USD 66.33 reported by MarketBeat, illustrating that some houses see limited upside from current levels while others remain more constructive on the stock’s medium-term potential.

From a performance standpoint, an analysis on September 14, 2026 by Note.com points out that Bristol-Myers Squibb’s stock closed at USD 64.10 on September 14, 2026, representing a 38.3 percent increase over the prior year’s price and an approximately 60 percent gain from the 52-week low of USD 42.60 registered on October 29, 2025 to the 52-week high of USD 68.09 observed on September 3, 2026.

For investors, this quantified move means that most of the rerating has already occurred: the one-year gain of 38.3 percent and the roughly 60 percent climb from the 52-week low toward the early-September high indicate that Bristol-Myers Squibb has already captured a substantial valuation uplift, making future performance more dependent on continued earnings delivery and how the market weighs patent and biosimilar risks.

Market capitalization and trading metrics as of September 14, 2026

Per CompaniesMarketCap data relayed for September 14, 2026, Bristol-Myers Squibb’s market capitalization stood at approximately USD 130.93 billion, placing the company among the larger global pharmaceutical firms by equity value.CompaniesMarketCap notes that this market cap level reflects a roughly 17.71 percent increase for 2026 compared with the prior year in its overview table.

Intraday dynamics on September 14, 2026 also show a relatively tight trading range: Ad-hoc-news citing NYSE closing data reports that Bristol-Myers Squibb shares traded between USD 63.30 at the low and USD 64.22 at the high during the regular session, with the closing price of USD 64.08 near the upper end of that band, suggesting steady buying interest even as the S&P 500 index slipped about 0.5 percent on the same date.

For liquidity and trading, this combination of a USD 130.93 billion market capitalization and an actively traded NYSE listing under the ticker BMY means that Bristol-Myers Squibb remains a core, large-cap healthcare exposure in many portfolios, with price movements closely tied to news on key therapies, guidance revisions and broader sector sentiment.

Stock level on the NYSE

On the primary listing venue, the New York Stock Exchange, Bristol-Myers Squibb stock (ticker BMY) closed at USD 64.08 on September 14, 2026, with the session ending at 3:59 p.m. Eastern Time, and the shares posting a 0.69 percent gain versus the prior close according to NYSE data summarized by Ad-hoc-news and price overviews.